| (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 |
|
|
|
|
|
95.07% |
| (D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide |
|
|
|
|
|
|
| (D-Trp8,D-Cys14)-Somatostatin-14 |
|
|
|
|
|
|
| (R)-Verapamil |
|
|
|
|
|
98.97% |
| [D-Trp8,Tyr11] Somatostatin |
|
|
|
|
|
|
| [D-Trp8] Somatostatin-14 |
|
|
|
|
|
|
| [Leu8,D-Trp22,Tyr25] Somatostatin-28 |
|
|
|
|
|
|
| [Nle8] Somatostatin (1-28) |
|
|
|
|
|
|
| [Nle8] Somatostatin (1-28) TFA |
|
|
|
|
|
99.86% |
| [Tyr11]-Somatostatin |
|
|
|
|
|
99.55% |
| [Tyr12] Somatostatin 28 (1-14) |
|
|
|
|
|
|
| [Tyr1]-Somatostatin-14 |
|
|
|
|
|
|
| AC-178335 |
|
|
|
|
|
|
| Alkyne-βAG-TOCA |
|
|
|
|
|
98.99% |
| AP102 |
|
|
|
|
|
|
| Axareotide |
|
|
|
|
|
|
| BIM 23052 |
|
|
|
|
|
99.76% |
| BIM-23027 |
|
|
|
|
|
99.76% |
| BIM-23056 |
|
|
|
|
|
99.98% |
| BIM-23056 TFA |
|
|
|
|
|
|
| BIM-23190 |
|
|
|
|
|
|
| BIM-23190 hydrochloride |
|
|
|
|
|
99.33% |
| BIM-23197 |
|
|
|
|
|
|
| BN-81674 |
|
|
|
|
|
|
| Branosotine |
|
|
|
|
|
|
| CH 275 |
|
|
|
|
|
99.52% |
| Cortistatin 14 (mouse, rat) |
|
|
|
|
|
99.45% |
| Cortistatin-14 TFA |
|
|
|
|
|
99.99% |
| Cortistatin-17 (human) |
|
|
|
|
|
99.04% |
| Cortistatin-29 (human) |
|
|
|
|
|
98.48% |
| Cortistatin-29 (rat) |
|
|
|
|
|
|
| Cortistatin-29 (reduced) |
|
|
|
|
|
98.12% |
| Cyclic SSTR agonist octreotide |
|
|
|
|
|
|
| Cyclosomatostatin |
|
|
|
|
|
99.56% |
| Cyclosomatostatin TFA |
|
|
|
|
|
|
| CYN 154806 |
|
|
|
|
|
99.90% |
| CYN 154806 TFA |
|
|
|
|
|
98.30% |
| Depreotide |
|
|
|
|
|
|
| Des-threoninol-octreotide |
|
|
|
|
|
|
| DOTA-EB-TATE |
|
|
|
|
|
95.42% |
| DOTA-JR11 |
|
|
|
|
|
99.14% |
| DOTA-LM3 |
|
|
|
|
|
99.37% |
| DOTA-LM3 TFA |
|
|
|
|
|
99.25% |
| DOTA-NOC |
|
|
|
|
|
99.22% |
| DOTAMTATE |
|
|
|
|
|
99.55% |
| FK962 |
|
|
|
|
|
99.89% |
| Ilatreotide |
|
|
|
|
|
|
| J-2156 |
|
|
|
|
|
99.88% |
| J-2156 TFA |
|
|
|
|
|
99.88% |
| JR11-PEG3-DOTA-PSMA-03 |
|
|
|
|
|
|
| JR11-PEG3-HBED-CC-PSMA-03 |
|
|
|
|
|
|
| L-054522 |
|
|
|
|
|
|
| L-779976 |
|
|
|
|
|
|
| L-796778 |
|
|
|
|
|
|
| L-796778 acetate |
|
|
|
|
|
98.00% |
| L-797591 |
|
|
|
|
|
|
| L-797591 hydrochloride |
|
|
|
|
|
99.81% |
| L-803087 |
|
|
|
|
|
99.66% |
| L-803087 TFA |
|
|
|
|
|
|
| L-817818 |
|
|
|
|
|
99.80% |
| L803 |
|
|
|
|
|
|
| Lanreotide acetate |
|
|
|
|
|
99.84% |
| Lanreotide diTFA |
|
|
|
|
|
|
| MAT2A-IN-1 |
|
|
|
|
|
|
| MAT2A-IN-2 |
|
|
|
|
|
|
| MAT2A-IN-3 |
|
|
|
|
|
|
| Mazisotine |
|
|
|
|
|
99.54% |
| Mazisotine tartrate |
|
|
|
|
|
|
| MK-1421 |
|
|
|
|
|
|
| MK-4256 |
|
|
|
|
|
99.07% |
| MMC(TMZ)-TOC |
|
|
|
|
|
|
| MMC(TMZ)-TOC TFA |
|
|
|
|
|
95.00% |
| Nendratareotide |
|
|
|
|
|
|
| Neuronostatin-13 (human) |
|
|
|
|
|
99.53% |
| NNC 26-9100 |
|
|
|
|
|
99.3% |
| NODAGA-LM3 |
|
|
|
|
|
99.65% |
| NODAGA-LM3 TFA |
|
|
|
|
|
|
| NOTA-Octreotide |
|
|
|
|
|
|
| NOTA-TATE |
|
|
|
|
|
|
| Octreotide dihydrochloride |
|
|
|
|
|
|
| Octreotide dimer (parallel) |
|
|
|
|
|
|
| Octreotide-d8 |
|
|
|
|
|
|
| Onzigolide |
|
|
|
|
|
|
| Pasireotide (aspartate) TFA |
|
|
|
|
|
|
| Pasireotide (diaspartate) |
|
|
|
|
|
|
| Pasireotide acetate |
|
|
|
|
|
99.92% |
| Pasireotide pamoate |
|
|
|
|
|
99.47% |
| PRL 2915 |
|
|
|
|
|
99.92% |
| PRL 3195 |
|
|
|
|
|
|
| RC-160 [Lys(Boc)] |
|
|
|
|
|
|
| Satoreotide |
|
|
|
|
|
98.80% |
| Seglitide |
|
|
|
|
|
99.30% |
| Seglitide acetate |
|
|
|
|
|
98.76% |
| Somatostatin-28 (1-14) |
|
|
|
|
|
99.75% |
| Somatostatin-28 (sheep, human rat mouse) |
|
|
|
|
|
99.67% |
| SRA880 |
|
|
|
|
|
98.22% |
| SRA880 free base |
|
|
|
|
|
|
| SST1 receptor antagonist-1 |
|
|
|
|
|
|
| SST1 receptor antagonist-2 |
|
|
|
|
|
|
| sst2 Receptor agonist-1 |
|
|
|
|
|
|
| SSTR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| SSTR2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| SSTR3 Agonist-1 |
|
|
|
|
|
|
| SSTR3 agonist-1 TFA |
|
|
|
|
|
|
| SSTR3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| SSTR4 agonist 2 |
|
|
|
|
|
99.39% |
| SSTR4 agonist 3 |
|
|
|
|
|
|
| SSTR4 agonist 4 |
|
|
|
|
|
|
| SSTR4 agonist 5 |
|
|
|
|
|
|
| SSTR4 agonist 6 |
|
|
|
|
|
|
| SSTR4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| SSTR5 antagonist 1 |
|
|
|
|
|
99.91% |
| SSTR5 antagonist 2 |
|
|
|
|
|
|
| SSTR5 antagonist 2 hydrochloride |
|
|
|
|
|
98.85% |
| SSTR5 antagonist 2 TFA |
|
|
|
|
|
|
| SSTR5 antagonist 3 |
|
|
|
|
|
|
| SSTR5 antagonist 4 |
|
|
|
|
|
|
| SSTR5 antagonist 6 |
|
|
|
|
|
|
| SSTR5 antagonist 7 |
|
|
|
|
|
|
| SSTR5 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr5 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Sstr5 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| SSTR5/TGR5-modulator-1 |
|
|
|
|
|
|
| Sucrose octasulfate |
|
|
|
|
|
|
| Tau conotoxin CnVA |
|
|
|
|
|
|
| TT-232 |
|
|
|
|
|
98.72% |
| TT-232 TFA |
|
|
|
|
|
|
| Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) |
|
|
|
|
|
|
| Tyr3-Octreotate |
|
|
|
|
|
99.76% |
| Veldoreotide |
|
|
|
|
|
|
| Veldoreotide TFA |
|
|
|
|
|
98.97% |
| Wy 41747 |
|
|
|
|
|
|
| Zavolosotine |
|
|
|
|
|
|
| Lanreotide |
|
|
|
|
|
98.86% |
| Octreotide pamoate |
|
|
|
|
|
|
| Octreotide |
|
|
|
|
|
99.96% |
| Octreotide-d8 TFA |
|
|
|
|
|
|
| Pasireotide |
|
|
|
|
|
99.94% |
| Pasireotide ditrifluoroacetate |
|
|
|
|
|
99.56% |
| Pasireotide L-aspartate salt |
|
|
|
|
|
97.0% |
| Cortistatin-14 |
|
|
|
|
|
99.98% |
| Sucrose octasulfate sodium |
|
|
|
|
|
98.0% |
| Angiopeptin |
|
|
|
|
|
|
| Angiopeptin TFA |
|
|
|
|
|
99.01% |
| Octreotide acetate |
|
|
|
|
|
99.92% |